Sign In
Buy BTAI
$1.26
-0.0400 (-3.08%)
At Close: Jun 23, 2026
FDA sets PDUFA action date for January 5, 2022
BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q1 2021 Results - Earnings Call Transcript
03:29pm, Monday, 10'th May 2021
BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q1 2021 Results - Earnings Call Transcript
BioXcel Therapeutics to Host First Quarter 2021 Operating and Financial Results Conference Call and Webcast
07:00am, Monday, 03'rd May 2021
NEW HAVEN, Conn., May 03, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intel
BioXcel Therapeutics Announces Presentations on SERENITY I & II at the 2021 American Psychiatric Association Annual Meeting
07:00am, Monday, 26'th Apr 2021
NEW HAVEN, Conn., April 26, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligenc
New York, New York--(Newsfile Corp. - April 16, 2021) - Levi & Korsinsky announces it has commenced an investigation of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) concerning possible breaches of fiduci
Why BioXcel Therapeutics Stock Is Plunging Today
02:54pm, Thursday, 01'st Apr 2021
Investors were not impressed with the biotech's latest clinical update.
FDA Gives Accelerated Review Tag To BioXcel's BXCL501 In Dementia-Related Agitation
09:06am, Monday, 15'th Mar 2021
The FDA has designated Breakthrough Therapy status to BioXcel Therapeutics Inc's (NASDAQ: BTAI) BXCL501, to treat agitation associated with dementia. The designation intends to expedite the devel
BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q4 2020 Results - Earnings Call Transcript
02:24pm, Thursday, 11'th Mar 2021
BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q4 2020 Results - Earnings Call Transcript
BioXcel Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
07:15am, Thursday, 11'th Mar 2021
New Drug Application (“NDA”) submitted to the U.S. Food and Drug Administration (“FDA”) for BXCL501 for the acute treatment of schizophrenia and bipolar disorder related agitation
Still Betting On BioXcel Therapeutics Stock
08:16pm, Monday, 08'th Mar 2021
We revisit BioXcel Therapeutics in-depth for the first time in five months. The company has seen several encouraging developments on the pipeline front and continues to receive favorable analyst comme
BioXcel Therapeutics to Host Fourth Quarter and Full Year 2020 Operating and Financial Results Conference Call and Webcast
07:00am, Thursday, 04'th Mar 2021
NEW HAVEN, Conn., March 04, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial int
BioXcel Therapeutics Provides Update on its BXCL501 Program for the Acute Treatment of Dementia Related Agitation
07:00am, Wednesday, 03'rd Mar 2021
Review of TRANQUILITY data show ed 30 mcg dose met statistical significance across multiple scales
BioXcel Therapeutics Appoints June Bray to Board of Directors
07:00am, Monday, 01'st Mar 2021
Former Allergan executive brings extensive global regulatory experience across multiple therapeutic areas Former Allergan executive brings extensive global regulatory experience across multiple therap
BioXcel Therapeutics Starts Testing BXCL501 In Mid-Stage Delirium-Related Agitation Study
11:46am, Thursday, 25'th Feb 2021
BioXcel Therapeutics Inc (NASDAQ: BTAI) initiated the Phase 2 PLACIDITY trial evaluating BXCL501 to treat delirium-related agitation. The 20 subject-trial is designed to evaluate the safety, effic
Live webcast to be held on February 19th from 11:00 am ET to 2:00 pm ET Live webcast to be held on February 19th from 11:00 am ET to 2:00 pm ET
